


SENSING AHEAD, CARING MORE

INVESTOR RELATIONS 2025



CGM

i·sens

Copyright © i-SENS, Inc. All Right Reserved.

00 PROLOGUE

- 01 | Corporate Identity
- 02 | Diabetic CGM Growth (1)(2)
- 03 | Non-diabetic CGM Growth (1)(2)
- 04 | Global CGM Competitiveness
- 05 | CareSens Air: Product Video



CareSens[®] Air

Real-time continuous glucose monitoring
Seamless management for a healthier life

Key Products

**BGM** | Blood Glucose Monitoring

A device for a quick blood glucose checks using fingertip samples

**CGM** | Continuous Glucose Monitoring

A skin-attached sensor for real-time tracking of glucose levels

Customer Segments

Type 1 Diabetes

Type 2 Diabetes

Prediabetes

People without Diabetes

World-class R&D capabilities

- Korea's first CGM developer
- Designed for world-class accuracy & usability
- 46% of R&D staff have master's or PhDs

Global network & manufacturing scale

- Expanding global networks via OEM/ODM/PL
- Global reach 114+ countries
- 2.5B BGM strips & 2M CGMs produced annually

Growth through global expansion

- Integrated BGM-CGM app boosts user retention
- Partner-led global distribution growth
- CGM for trials builds medical ecosystem

The global diabetic population is growing, primarily driven by Type 2 Diabetes

Type 1 Diabetes (Congenital type)

Primarily develops in children and adolescence



- Insulin is not secreted by the pancreas
- An **autoimmune disease** that prevents glucose from being absorbed into cells

Type 2 Diabetes (Acquired type)

Primarily occurs in middle and old age
→ Now increasingly seen in younger generations



Obesity-related

Caused by adipocyte-induced insulin resistance



Other causes beyond obesity


Aging, genetics, lifestyle, mental health, etc.

- Insulin resistance due to acquired factors
- A **metabolic disease** characterized by reduced insulin

Type 1 diabetes is primarily caused by genetic factors,
While Type 2 diabetes is primarily caused by changes in lifestyle

✓ Global Diabetic Population Forecast

(Unit: 100Mn people)




✓ Global Diabetes Prevalence



The Global diabetic population continues to grow, driven primarily by Type 2 Diabetes

Expanded diabetes insurance coverage is driving CGM market growth

Growing Diabetes Market Size Driven by Diabetes Insurance Coverage



CGM Usage Among US Diabetes Patients

Despite broad insurance coverage in the U.S., CGM adoption remains low.

Type 1 Diabetes Patients



Less than 60%

Type 2 Diabetes Patients

Insulin ≥ 3 Times/Day



Less than 50~55%

Based Insulin Users



Less than 20~25%

High Hypoglycemia Risk



Less than 5%

Broader coverage is expected to drive CGM uptake and market growth

Source: Mordor Intelligence (via Gil Korea), 2024, Dexcom, Abbott

Global CGM Insurance Coverage for Type 2 Diabetes

Countries with Insurance Coverage

Country	Coverage Eligibility
U.S.	<ul style="list-style-type: none"> All Insulin Users Non-insulin users with a history of hypoglycemia
France	<ul style="list-style-type: none"> Insulin users(1-2x/day) with poor glucose control, Basal insulin users
U.K.	<ul style="list-style-type: none"> Insulin users(≥2 times/day) with a history of hypoglycemia
Germany	<ul style="list-style-type: none"> Users on basal insulin + oral glucose-lowering drugs
Canada	<ul style="list-style-type: none"> Multiple daily insulin users in Quebec*


Countries Undergoing Insurance Coverage Discussions

Country	Coverage Eligibility
Korea	<ul style="list-style-type: none"> Reviewing 70% reimbursement for CGM
Canada	<ul style="list-style-type: none"> Discussion on nationwide CGM coverage expansion
Australia	<ul style="list-style-type: none"> Policy discussions to expand CGM subsidies
Brazil	<ul style="list-style-type: none"> CGM under review by national committee for public coverage

CGM is widely covered for Type 1 Diabetes, with coverage expanding to Type 2

Global CGM Market Outlook


(Unit: USD Bn)



* First public reimbursement coverage for adult type 2 diabetes (November 2025)

Source: Medicare, NICE, National Health Insurance Service, Australian Parliament House (2024), Health Canada, Market Research Future, CONITEC, KKH

Rising demand for insulin resistance management → CGM needed even for normoglycemic individuals



Driven by modern lifestyles, insulin resistance
Contributes to diabetes and other related conditions


Metabolic Healthcare: A New Approach to Insulin Resistance

Proactively improving metabolic health to lower insulin resistance

Prediabetes


Elevated blood glucose due to insulin resistance,
but not high enough for a diabetes diagnosis.

Prevalence in Korea (2022)



Global Prevalence Outlook


(Unit: 100Mn people)




Metabolic Syndrome

A cluster of metabolic disorders (e.g., hypertension, obesity),
often driven by insulin resistance.

Prevalence in Korea (2021)



Global Prevalence (2024)



Blood glucose is a key indicator of insulin resistance

Principle of Insulin Resistance



When insulin fails to transport glucose into cells,
resistance develops and blood glucose rises



Blood glucose is
The clearest marker
of insulin resistance

Rising demand for CGM to monitor blood glucose levels


How CGM Works



Sensor attachment



Real-time glucose data sent to
smartphone app



24/7 monitoring
and alerts

Enables 24/7 real-time glucose monitoring

Improve insulin resistance through tailored insights and glucose stability

Source: Korean Society of Cardiovascular and Metabolic Diseases, Korean Diabetes Association, International Diabetes Federation (IDF), Huamani et al., Scientific Reports

CGM use is expanding from diabetes care to general health and wellness

News Growing CGM Adoption among Non-diabetics for Wellness Tracking

Lifestyle change is key—medication alone isn't enough.

Continuous Glucose Monitoring (CGM) is gaining attention not only in diabetes care but also for proactive health management. By identifying glucose spikes from specific foods, users can adjust their diets and improve long-term metabolic health.

→ CGM for Diabetes Prevention

Why are non-diabetic users, especially young women, adopting CGM?


Many find value in using CGM to understand how food, exercise, and sleep affect their bodies. Popular content shows how CGM helps optimize workouts, improve eating habits, and track fitness goals.

→ CGM for Lifestyle & Wellness Optimization

Source: Press Release

Global Digital Healthcare Market Outlook

(Unit: USD Bn)



Digital health expansion is accelerating access to metabolic care

Source: Grand View Research


Rise of a CGM-driven Digital Healthcare Ecosystem



CGM is expanding from diabetes care to consumer wellness

Source: Internal data

User Convenience vs. CGM Accuracy



	i.sens		dexcom	Abbott	Medtronic
	CareSens Air	CareSens Air 2 (Upcoming)	G7	Libre 3+	Simplera
Sensor Size	W35.2 x H19.2 x T5.0 mm	W23.6 x H15.8 x T2.9 mm	W27.3 x H24.0 x T4.6 mm	D21.0 x T2.9 mm	W28.7 x H28.7 x T4.8 mm
Useful Life	15 Days	18 Days	10 Days	15 Days	7 Days
Calibration	Supports Calibration If Needed	Supports Calibration If Needed	Optional Calibration	Not Available	Optional Calibration
Warm-up Time	30 Minutes	20 Minutes	30 Minutes	1 Hour	2 Hour
Data Transfer Interval	Every 5 Minutes	Every 5 Minutes	Every 5 Minutes	Every 1 Minutes	Every 5 Minutes
MARD*	8.7%	Clinical trial completed & preparing for MFDS/CE approvals	8.2%	8.2%	10.2%
Global M/S			35–40% (Est.)	40–45% (Est.)	10–15% (Est.)



▶ [Watch Video](#)



01 i-SENS, The First CGM Company in Korea

- 01 | Growth History
- 02 | ManPower
- 03 | Product Lineup
- 04 | Business Structure and Key Customers
- 05 | Production Infrastructure
- 06 | POCT Product Overview
- 07 | Business Performance
 - 1) 2025 Financial Summary
 - 2) Quarterly Earnings
 - 3) Global Revenue by Region
 - 4) 2026 Financial Preview



CareSens[®] Air


Real-time continuous blood glucose monitoring system
CareSens Air

i-SENS is emerging as a global CGM leader with proprietary technology and scalable production



Annual Revenue Trend


(Unit: KRW 100Mn)




Note: K-IFRS standard, 2000~2009 years are K-GAAP standard
Source: Internal data

i-SENS is led by global experts and powered by strong in-house R&D

Key Pioneers in Electrochemical CGM Innovation



Workforce Composition and R&D Investment




*An award presented by the American Chemical Society (ACS) to researchers who have made globally influential achievements, signifying the highest level of authority in the chemical field.


**Nitric Oxide, a gaseous molecule in the body, plays a crucial role in vasodilation, immune regulation, and thrombosis inhibition. Applying this to CGM prevents the sensor from being recognized as a foreign substance by the body, thereby increasing the CGM's lifespan.
Source: Internal data

BGM and CGM complement each other in managing blood glucose, with unique strengths and use cases

Daily Glucose Monitoring Routine

Stable glucose management requires both BGM and CGM → Patients may test with BGM up to 8 times daily




Product	BGM		CGM	
Category	 Strip	 Meter	 First CGM Developed and Launched in Korea Glucose Sensor 4-6mm Skin (1-2mm) Fat (2-15mm)	 Wireless Transmitter 
Pros and Cons	<div> <div>Advantage</div> <div>  Low Price </div> </div> <div> <div>Disadvantage</div> <div>  High Accuracy </div> </div> <div> <div>Disadvantage</div> <div>  Fingerstick Pain </div> </div> <div> <div>Disadvantage</div> <div>  Frequent Measurement </div> </div> <div> <div>Disadvantage</div> <div>  No Trend Visibility </div> </div>		<div> <div>Advantage</div> <div>  No Fingerstick Pain </div> </div> <div> <div>Advantage</div> <div>  High/Low Glucose Alerts </div> </div> <div> <div>Advantage</div> <div>  Trend Visibility </div> </div> <div> <div>Disadvantage</div> <div>  High Price </div> </div> <div> <div>Disadvantage</div> <div>  Lower Accuracy than BGM </div> </div>	
Target Users	Type 1 and 2 diabetes patients		Type 1 and 2 diabetes, prediabetes, general public	
Measurement Method	Measures glucose by obtaining a blood sample		Measures glucose continuously via a sensor	
Measurement Site	Fingertip		Back of upper arm	
Measurement Sample	Capillary blood		Interstitial fluid (blood X)	
Replacement Cycle	Single use		15 days from sensor attachment	

Source: Internal data

Own brand & OEM/ODM channels → Expand BGM OEM/ODM references to CGM

Leading BGM Market Share in Korea (over 50%)




Note: Based on Q4 2025 revenue
Source: Internal data

Annual production capacity of 2.4 billion BGM strips and 2 million CGM sensors

BGM & CGM Production Capacity

i.sens



Note: Average Daily Production Quantity × Working Days × Operating Months = Annual Total Production Capacity. The above production capacity is based on a 1 shift (8h of work/day)
Source: Internal data

Installed analyzers driving recurring cartridge sales → Key growth driver for POCT

POCT Product Lineup

A diverse POCT product lineup and the potential for continuous revenue from diagnostic equipment requiring consumables.

High-Value Professional Diagnostic Products

Hospital Diabetes Management POCT Products



Clinical Chemistry Analyzer

- Analytes: HbA1c, *ACR, GA, CRP
- All-in-one cartridge for fast and accurate results
- Rapid turnaround time (HbA1c: 4min 20sec, ACR: 7min)

Global Market Size
: USD 0.98Bn



BGM for Hospitals

- Hospital-use device for blood glucose & ketone measurement
- Supports Wi-Fi and USB for real-time data transfer and automatic software updates, enabling seamless hospital data integration

PT/INR Coagulation Testing Solutions



PT/INR Blood Coagulation Meter

- Product of U.S. subsidiary, 'CoaguSense
- Prothrombin Time tests: Testing for bleeding disorders, including hemophilia and coagulation abnormalities, primarily used for patients on warfarin

Global Market Size
: USD 1.69Bn



Blood Electrolyte Analyzer

- Launched in 2009
- **No.1 in Korea by installed base**
- Measures: Hct, Na, K, Cl (existing) + Ca, Mg (in development)

Global Market Size: USD 2.84Bn



Blood Gas Analyzer

- Upgraded model launched in 2020
- Measures: pH, pCO₂, pO₂, Hct, Na, K, Cl, iCa, Glucose, Lactate



Immunoassay Analyzer

- Detects key cardiovascular biomarkers
- **Expandable platform for future marker integration**


Global Market Size: USD 1.81Bn

Sustained Cartridge-Driven Growth

POCT Revenue Trend

Achieved KRW 46.8 billion in 2025 with a 15.6% CAGR('16~'25)


(Unit: KRW 100Mn)



Cartridge Product Sales and Share Trends

Cartridges Account for 45% of POCT Sales

(Unit: KRW 100Mn)



*ACR (Albumin/Creatinine Ratio): The ratio of albumin to creatinine levels, enabling a more accurate diagnosis of kidney function

Note1: USD 1 = KRW 1,400, Note2: Global Market Size (2024)

Based on Markets and Markets, K-HID, QYR, Data Bridge, Horizon Grand View Research, Kalorama, Biomerieux and Internal data

Consolidated Income Statement

(Unit: KRW Mn)

구분	2023	2024	2025	YoY
Revenue	265,120	291,138	315,445	8%
Cost of Sales	159,061	177,604	190,184	7%
	60%	61%	60%	
Gross Profit	106,059	113,534	125,261	11%
	40%	39%	40%	
SG&A	95,130	110,876	117,375	6%
	36%	38%	37%	
Operating Profit	10,929	2,658	7,887	212%
	4%	1%	3%	
Non-operating income	-4,797	-1,005	-18,556	
Income tax expense	2,728	3,605	-3,979	
Net Income	3,404	-1,953	-6,691	-243%
	1%	-1%	-2%	

Note: K-IFRS Consolidated Basis

Key Highlights

Revenue

- **CGM Revenue: KRW 17.6Bn**
(Domestic KRW 10.9Bn, Overseas KRW 6.7Bn)

- **Annual Capacity of 2Mn units Secured**
(Completion of automated production line at Songdo 2 Plant)


P&L

- **Gross Profit Increase**
Increase in gross profit driven by higher CGM sales and improved profitability of overseas subsidiaries
Margin expansion limited due to increased other expenses related to facility investment and production capacity expansion

- **Operating Profit Increase**
Operating profit increased by KRW 5.2Bn
R&D and patent/legal-rated expenses increased (KRW 5.4Bn)

- **Non-operating Items**
Decrease in disposal and valuation gains (-KRW 16Bn YoY)
Increase in equity method losses (KRW 0.8Bn)
Recognition of income tax benefit due to increased tax refunds and carryforward tax credits

Quarterly Revenue




Q4 2025 Earnings Results

- Revenue grew by 2.9% YoY
- Operating profit of KRW 2.1Bn (Turned to profit)
- Net loss of KRW 8.9Bn (Continued loss)

Note: K-IFRS Consolidated basis

Quarterly Operating Profit



Q4 2025 Earnings Review

- CGM revenue growth and expansion of overseas sales drove revenue increase of approximately KRW 2.3Bn YoY
- Operating profit turned to profit on higher sales and improved overseas subsidiary profitability despite higher R&D and clinical costs
- Net loss was driven by non-cash valuation losses and goodwill impairment among non-operating items


Revenue Breakdown by Region - 2025

● i-SENS Overseas Subsidiaries

■ 2024

■ 2025

(Unit: KRW 100Mn)



Note: K-IFRS Consolidated basis

CGM overseas sales growth and revenue expansion across all business segments, along with cost reduction initiatives
Laying the foundation for full-scale CGM business growth through clinical expansion and increased capacity

Key Highlights

Revenue

- **Headquarters Revenue Growth**

Revenue growth across all business segments including CGM
Ongoing participation in BGM/CGM overseas tenders and reimbursement listings in key markets

- **Subsidiary Revenue Growth**

Revenue growth expected across most subsidiaries YoY

CGM

- **2026 CGM Revenue Target: KRW 40.0Bn** (Domestic 16.0Bn / Overseas KRW 24.0Bn)
- **2025 CGM Revenue: KRW 17.6Bn** (Domestic KRW 10.9Bn / Overseas KRW 6.7Bn, Exceeded the initial target by 17.3%)
- **2026 Key Events:**
Q1 : Completed CGM supply agreement with LifeScan, initiated CareSens Air 2 U.S. pilot trial, completed CGM pilot trial in China
Q2 : MFDS and CE submissions for pediatric use expansion of CareSens Air, initiate CGM pivotal trial in China
3Q : MFDS and CE approvals for pediatric use expansion of CareSens Air, complete CareSens Air 2 U.S. pilot trial, CGM submission to NMPA, China
4Q : Initiation of CareSens Air 2 U.S. pivotal trial

Manufacturing

- **CGM Production Capacity: 2Mn → 5.4M units in Q1 2027** (3.4M units CareSens Air 2 sensors)
Strengthening global supply stability in response to rising demand

Cost Management

- **Margin Improvement through Cost Reduction**
BGM COGS savings via overseas production (Vietnam, China): 45% of total production in 2026, to expand further

02 Advancing as a Global Top-Tier CGM Company

01 | CGM Future Plans

02 | CGM Global Launch Plan

03 | Global Market Expansion Strategy

- 1) Partnerships with Global Players
- 2) Support for Global Clinical Trials
- 3) Localized Manufacturing Capabilities
- 4) Open Connected Ecosystem

04 | Vision & Value-up Plan



CareSens[®] Air 2




Real-time continuous blood glucose monitoring system
CareSens Air

CGM Future Plans CareSens Air Development and Launch Timeline

CareSens Air aims for age 2+ approval in 2026 following domestic and CE approvals

CareSens Air 2 launches in Korea in 2027, followed by Europe in 2027 and the U.S. in 2028

CareSens Air Development and Launch Timeline



*OTC(Over the Counter): Medicines available without a prescription, sold at pharmacies or other retail channels

**Based on current plans; timelines are subject to final confirmation as the clinical target has been changed from CareSens Air 1 to CareSens Air 2

Note: Upgrade includes: Reduced warm-up time (2h → 30 min), supports calibration if needed, non-adjunctive use approved


CareSens Air

- 2025: Launched in 27 countries
- 2026: Launch in 9 additional countries



CareSens Air 2

- 2027: Launch in South Korea and Europe
- 2028: Launch in U.S.



Source: Internal data

Expanding global presence through multi-faceted strategies

1

Enhancing Access and Global Reach
Through Strategic Partnerships

SAMSUNG

CareMedi
케어메디

arkray



DONG-A ST


kakao healthcare

embecta

HANDOK

Lifescan


2

Accelerating Ecosystem Growth
via CGM Supply for Clinical Trials

3

Building Local Manufacturing Capabilities
Through Technology Transfer

4

Fostering Long-term Growth Through
an Open Connected Ecosystem


Customer acquisition, distribution expansion, clinical adoption, and manufacturing competitiveness
→ Accelerating Global CGM Revenue Growth

Source: Internal data

Expanding partnerships based on globally competitive CGM products

1 Smart Device CGM Integration Partnership

Unified tracking of diet, activity, and glucose data



Driving B2C Expansion via Global Smart Health Partnerships

3 Distribution Partnership via CGM-Linked Product Sales


AI-based glucose coaching connected to i-SENS product sales



Expanding Global Reach through Data-Linked Sales Channels

2 R&D Partnership for Artificial Pancreas Development


Joint development of AID (Automated Insulin Delivery) system



Targeting High-Risk Patients with Integrated CGM-Pump Solutions

4 OEM & ODM Distribution Partnership

Establishing distribution infrastructure through partnerships



Rapid market entry and revenue expansion via OEM/ODM model

Strengthening product competitiveness → Expanding partnerships → Accelerating global revenue growth

Expanding clinical adoption through accumulated clinical data → CGM revenue growth

i.sens CGM Provided
For glucose monitoring



Hospitals, Research Centers, and CROs

Clinical Trial A

Clinical Trial B

Clinical Trial C

...

Trials conducted with CGM in use
Real-time validation of drug/device efficacy
Contributing to CGM as global standard



Medical Ecosystem
Expanding presence
In the global
Medical ecosystem

Revenue Generation

(Creation of new revenue streams)



Trial supply
To hospitals
And research sites



Drives new customer
Acquisition
And contract sales

Brand Building via Clinical Trials (incl. PMCF*)

→ Generating promotional and marketing impact



Product use
in clinical trials



Build objective trust
via clinical experience



Reinforce field
Credibility
via repeated use



'Strengthen
CareSens Air
brand trust

Expand promotional effect through user experience

User Data Collection

→ Algorithm Optimization



Collecting
diverse user data



Ongoing
algorithm
refinement

Expansion of hospital and institutional contracts based on clinical supply → New revenue generation

*PMCF: Post-Market Clinical Follow-up, Periodic clinical follow-up observation after medical device market release
Source: Internal data

Leveraging BGM localization know-how to expand CGM reach

Benefits of Establishing a Local Production System

Price competitiveness through tariff reduction and local production


Market entry facilitation via public procurement and regulatory alignment

Supply stability via local manufacturing, enabling large-scale contracts

Distribution network expansion through local partnerships

Local manufacturing partner-based lock-in structure → enabling long-term supply agreements and recurring revenue


BGM Local Production System



Local manufacturing-based
CGM global expansion
→ Emerging market revenue growth

Source: Internal data

Starting with EMR integration, connecting to digital healthcare across medical, insurance, and wellness to create real value



Creating true value through connectivity to digital healthcare expanding into medical, insurance, and wellness

i·sens

**Achieve CGM sales growth and market revaluation
with a mid- to long-term PSR vision of 4**

('25 PSR 1.4x)



Pipeline

Product Development and Launch

- CareSens Air: Expanded age indication in 2026
- CareSens Air 2
 - ✓ Approval and launch in Korea and Europe in 2027
 - ✓ Approval and market entry in the U.S. in 2028



Sales Growth

2030 CGM Sales

KRW 1 Trillion

Mid- to long-term strategic direction considering global approval timelines and production capacity expansion



Shareholder Return

Shareholder Return Rate

30%

Aim for the mid- to long-term within a scope that preserves growth investment and financial stability

2030 Cumulative Treasury Stock Cancellation

KRW 30 Billion

In the CGM growth phase, a sales-based valuation (PSR) is appropriate, with re-rating potential

03 APPENDIX


01 | Company Overview

02 | Consolidated Financial Statements



CareSens[®] Air 2


Global Corporate Structure



Source: Internal data

Company Overview

Company Name	i-SENS [KOSDAQ 099190]
Representative Directors	Geun Sig Cha(CEO), Hakhyun Nam(CEO)
Principal Business	Electrochemical Diagnostic Biosensor
Date of Establishment	May 2000
Listing Date	January 2013
Capital Stock	KRW 13.8B
Number of Employees	960
Address	43, Banpo-daero 28-gil, Seocho-gu, Seoul
Website	www.i-sens.com





Balance Sheet

(Unit: KRW Mn)

Category	2021	2022	2023	2024	2025
Current Assets	207,653	217,187	207,526	270,907	253,710
Non-current Assets Held for Sale	-	-	10,245	4,672	4,672
Non-current Assets	221,526	232,383	281,045	315,289	319,281
Total Assets	429,179	449,570	498,816	590,868	577,663
Current Liabilities	38,391	74,563	139,305	112,085	166,913
Non-current Liabilities	106,048	70,251	56,016	135,802	72,429
Total Liabilities	144,439	144,814	195,321	247,887	239,342
Capital Stock	6,869	6,877	13,759	13,821	13,868
Capital Surplus	46,205	47,013	41,697	42,971	44,395
Other Equity Items	(6,569)	(4,653)	(5,092)	2,701	2,379
Other Comprehensive Income	23,303	22,631	21,861	56,760	55,580
Assets Held for Sale Related Other Comprehensive Income	-	-	548	250	250
Retained Earnings	198,525	213,942	211,577	208,192	198,775
Non-controlling Interests	16,408	18,946	19,145	18,286	23,074
Total Equity	284,740	304,756	303,495	342,981	338,321

Note: K-IFRS Consolidated Financial Statements Standard

Income Statement

(Unit: KRW Mn)

Category	2021	2022	2023	2024	2025
Revenue	232,935	264,837	265,120	291,138	315,445
Cost of Revenue	130,870	159,351	159,061	177,604	190,184
Gross Profit	102,065	105,486	106,059	113,534	125,261
Selling and Administrative Expenses	67,238	85,679	95,130	110,876	117,375
Operating profit	34,827	19,807	10,929	2,658	7,887
Non-Operating Profit/Loss	(2,653)	1,696	(2,818)	739	(16,049)
Equity Method Gains and Losses	(1,433)	(2,350)	(1,978)	(1,745)	(2,507)
Profit before Income Tax	30,741	19,153	6,132	1,652	(10,669)
Income Tax Expense	5,590	3,245	2,728	3,605	(3,979)
Net Income	25,151	15,908	3,404	(1,953)	(6,691)